Merck's Blockbuster Cancer Drug Keytruda Secures FDA Approval For Biliary Tract Cancer
Portfolio Pulse from Vandana Singh
The FDA has approved Merck & Co Inc's cancer drug, Keytruda, for use in treating locally advanced unresectable or metastatic biliary tract cancer (BTC). The approval was based on results from the Phase 3 KEYNOTE-966 trial, which showed a significant improvement in overall survival rates. This marks the sixth indication for Keytruda in gastrointestinal cancers. Merck also released data from the Phase 3 KEYNOTE-564 trial evaluating Keytruda for certain patients with renal cell carcinoma.
November 01, 2023 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's Keytruda has received FDA approval for treating biliary tract cancer, which could potentially increase the company's market share and revenues.
The FDA approval of Keytruda for treating biliary tract cancer expands its indications, potentially increasing its market share and revenues. This is positive news for Merck and could lead to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100